“Consisting Essentially Of:” Expanding the Scope of Indefiniteness

Nov 8, 2019

Reading Time : 3 min

In December 2014, HZNP Medicines LLC (“Horizon”) brought suit against Actavis Laboratories UT, Inc. (“Actavis”) in the District of New Jersey, alleging infringement of a group of its patents relating to the formulation and method-of-use of a drug for treating osteoarthritis. This suit was in response to Actavis having previously filed an ANDA with a Paragraph IV certification, stating that Horizon’s patents-at-issue were invalid and that they would not be infringed by Actavis’ generic product. The district court issued its Markman order on August 17, 2016, finding three terms in Horizon’s asserted claims indefinite and thus ruling in summary judgment that the formulation patents were invalid.

On appeal, the Federal Circuit affirmed.

The Federal Circuit addressed whether three key terms met the definiteness requirement under 35 U.S.C. 112 (b). For the first term, “impurity A,” Actavis successfully argued at the district court that the term “impurity A” is indefinite because neither the claims nor intrinsic evidence defined it. Horizon argued that a person of ordinary skill in the art (POSITA) would recognize “impurity A” as “USP Related Diclofenac Compound A” based on extrinsic evidence, including available pharmacopeias. The Court disagreed with Horizon for several reasons. The Court concluded that the term’s usage within the challenged claims does not make clear that it refers to any particular compound. Nor does the specification provide a clue as to the impurity’s identity. Also, the Court noted that the specification and claims referred to “impurity A” in quotes, indicating that its actual composition was not known. Therefore, the term “impurity A” is indefinite.

Second, the Court held a set of claims invalid for indefiniteness because they regarded the degradation of “impurity A” through the term “degrades at less than 1% over 6 months.” The Court reasoned that because “impurity A” itself was unidentified and therefore indefinite, it followed that any claim regarding its degradation would also be invalid as indefinite.

Third, the Court addressed the effect of the transitional phrase “consisting essentially of” on indefiniteness. The transitional phrase “consisting essentially of” serves a middle ground between closed-ended claims using the phrase “consisting of” and open-ended claims using the phrase “comprising.” The Court states that here it means that the invention necessarily includes the listed ingredients within the claims, but could include unlisted ingredients that do not materially affect the basic and novel properties of the invention. Characterizing the patents’ basic and novel property as superior drying time of the compositions of the invention, the Court applied the Nautilus test for indefiniteness (i.e. failing to inform a POSITA, with reasonable certainty, the scope of the invention) to the drying time. Though Horizon argued that the indefiniteness test should apply only to the claims and not to the basic and novel property of the invention, the court reasoned that because the claim language used the phrase “consisting essentially of,” evaluating definiteness of the claim language inherently necessitated an analysis of the basic and novel property as well. Because the patent provided for two different methods of evaluating drying time and the two methods provided inconsistent results, the court held that the underlying basic and novel property of the invention was indefinite, hence making the claims indefinite and invalid as well.

HZNP Medicines LLC, Horizon Pharma USA, Inc. v. Actavis Laboratories UT, Inc., 2017-2149, 2017-2152, 2017-2153, 2017-2202, 2017-2203, 2017-2206 (Fed. Cir. Oct. 10, 2019)

Practice Tip: When a claim refers to an impurity, the remainder of the claim or specification should provide reference to a specific, identifiable compound. Further, when using the transition phrase “consisting essentially of” to list a set of elements, an indefiniteness analysis can extend to the specification and the basic and novel properties of the invention described therein. Thus, patent applicants should make sure to clearly delineate such properties in the written description.

Share This Insight

Previous Entries

IP Newsflash

March 24, 2025

The Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) final written decision holding that the prior art exception of AIA Section 102(b)(2)(B) does not apply to a prior sale by an inventor when the sale is conducted in private. According to the Federal Circuit, a sale must disclose the relevant aspects of the invention to the public to qualify for the prior art exception of Section 102(b)(2)(B).

...

Read More

IP Newsflash

March 21, 2025

Under the Lanham Act, a plaintiff who prevails on a trademark infringement claim may be entitled to recover the “defendant’s profits” as damages. The Supreme Court in Dewberry Group, Inc. v. Dewberry Engineers Inc. unanimously construed “defendant’s profits” in 35 USC § 1117(a) to mean that only the named defendant’s profits can be awarded, not the profits of other related corporate entities. The Court, however, left open the possibility that other language in § 1117(a) may allow for damages linked to the profits of related entities, if properly raised and supported.

...

Read More

IP Newsflash

March 13, 2025

In a series of rulings on a motion in limine, the District of Delaware recently distinguished between what qualifies as being incorporated by reference and what does not for the purposes of an anticipation defense. In short, a parenthetical citation was held to be insufficient, while three passages discussing a cited reference met the test.

...

Read More

IP Newsflash

March 4, 2025

On February 28, 2025, the USPTO announced that it was rescinding former Director Vidal’s 2022 memorandum on discretionary denials by the Patent Trial and Appeal Board. The 2022 memorandum effectively narrowed the application of discretionary denials in cases with parallel district court litigation by specifying instances where discretionary denial could not be issued. With the withdrawal of the memorandum, individual PTAB panels will regain flexibility in weighing discretionary denials. While the long-term effect of that increased flexibility is not yet known, the immediate effect is likely to be a shift towards the discretionary analysis applied by PTAB panels before the issuance of the memorandum.

...

Read More

IP Newsflash

March 3, 2025

A District of Delaware judge recently granted a defendant’s motion to include a patent prosecution bar in its proposed protective order after determining that litigation counsel’s ability to practice before the Patent Office—without ever having represented the plaintiffs at the Patent Office in the past—weighed heavily in favor of the bar.

...

Read More

IP Newsflash

February 12, 2025

The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to satisfy the written description requirement. In so doing, the Federal Circuit explained that written description and enablement are evaluated based on the subject matter that is claimed, not the products that practice those claims. As a result, the patentee was not required to describe unclaimed, later-discovered features of the accused products despite the broad language in the claims that undisputedly covered the products.

...

Read More

IP Newsflash

January 24, 2025

The District of Delaware recently rejected a patentee’s argument that non-production of an opinion letter from counsel, combined with knowledge of the patent, warranted a finding that defendant induced infringement.

...

Read More

IP Newsflash

January 17, 2025

The District of Delaware recently denied a motion to dismiss a patent infringement complaint involving gene editing technology that sought relief under the Safe Harbor Provision of the Hatch-Waxman Act. Specifically, the court found the patentee’s complaint sufficiently alleged at least some uses of the claimed technology that, when taken as true, were not solely uses of a “patented invention” that were “reasonably related” to an FDA submission.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.